InforMedix's Med-eMonitor To Play Critical Role In Improving Patient Drug Safety

Med-e-Monitor Provides Medication Compliance and Care Plan Adherence Rates in Excess of 90%

ROCKVILLE, MD – InforMedix Holdings, Inc. today shared the capability of its Med-e-Monitor System to enhance patient drug safety. Med-e-Monitor helps ensure the "Five Rights to Patient Drug Safety" – The Right Patient, given the Right Drug, in the Right Dose, at the Right Time, through the Right Route of administration.

The National Council for Patient Information and Education states that outpatient medication non-compliance rates average 50% and result in over 125,000 preventable deaths and tens of billions of dollars in unnecessary costs each year. On average, a single medication error can cost the healthcare system $4,600. Congress and the FDA have been intensively focused on patient drug safety in recent weeks, and the FDA has announced the creation of a new, independent Drug Safety Oversight Board to better ensure safe drug administration to patients.

The Med-eMonitor System provides each patient with an individualized daily treatment regimen involving medication prompts and drug dispensing, behavioral prompts, medical education, and health status questionnaires. It provides warnings and alerts to the patient when the wrong drug is about to be taken, and provides warnings and alerts when a drug is missed to both the patient and the care coordinator. The System also captures side effect and adverse event information, provides instant alerts and recommendations for action to the patient, and triggers e-mail alerts to care managers and physicians to prompt urgent interventions that improve safety.

The Med-eMonitor System enables the capture and correlation of critical dose-response data, including the correlation of patient medication compliance data with patient reported outcomes, side effects, adverse events, and laboratory data, which assist in the scientific evaluation of a particular drug's safety profile. Med-eMonitor also has medication compartments adjacent to the informational display on the device, whereby the display indicates and points to the correct compartment to access the medication at the time of administration, further improving safe medication administration.

Dr. Bruce Kehr, CEO of InforMedix stated, "Studies conducted in Congestive Heart Failure and Schizophrenia populations have shown that the Med-e-Monitor System provides medication compliance and care plan adherence rates in excess of 90%. Our alliance with McKesson BioServices, a leader in patient medication systems, further supports the success of the Med-eMonitor System in this capacity."

InforMedix has developed the Med-eMonitor System to provide real-time medical management and patient communications for clinical drug trials and disease management markets. InforMedix has integrated a portable patient-interactive monitoring device, hardware, software and networked communications system to enable pharmaceutical and biotechnology companies, medical researchers, and disease management programs to efficiently monitor and manage patients' medication compliance, protocol adherence, clinical response, and drug safety. Med-eMonitor is specifically designed to improve patient medication compliance and protocol adherence in clinical drug trials and disease management programs. The Med-eMonitor System leverages InforMedix's strong intellectual property consisting of 15 issued patents and 14 patents pending. InforMedix's patents have been cited as prior art by patent examiners in over 150 other issued patents.

To find out more about InforMedix, Inc. (OTCBB: IFMX), visit our website at www.informedix.com.

Source: InforMedix, Inc.